Register
Login:
Share:
Email Facebook Twitter

Josh Mahony from IG sums up the forces driving markets and currencies Watch here

Leading commentator Josh Mahony from IG - are we seeing a US$ revaluation?


Immupharma Share Chat (IMM)



Share Price: 48.125Bid: 47.25Ask: 49.00Change: 0.00 (0.00%)No Movement on Immupharma
Spread: 1.75Spread as %: 3.70%Open: 46.00High: 48.00Low: 44.00Yesterday’s Close: 48.125


Share Discussion for Immupharma


Thread View

Please login or register to post a message on Share Chat.

Posts per page:


Ridiculous
Posts: 38
Off Topic
Opinion:No Opinion
Price:48.125
Thanks
Fri 20:21
Thanks for your input , folks. I've held Immupharma for quite some time, partly because of some of their innovative approach. I've been building up my holding and WANT them to succeed. The timing was what made me actually raise the subject. Onwards and , hopefully, upwards!
 
PinWiz
Posts: 77
Off Topic
Opinion:No Opinion
Price:48.125
RE: Suspicious?
Fri 20:01
OB it makes sense to me all IMO of course!
oilbagger
Posts: 99
Observation
Opinion:Strong Buy
Price:48.125
RE: Suspicious?
Fri 19:32
PinWiz - looks like a few of us have jumped to the same conclusions. Hope there is something in it.
Should be an interested start to next week.
oilbagger
Posts: 99
Observation
Opinion:Strong Buy
Price:48.125
RE: Suspicious?
Fri 19:30
See Rule 17 or paragraph (g) of Schedule 2 in

http://www.londonstockexchange.com/companies-and-advisors/aim/advisers/aim-notices/aimrulesforcompaniesjan16.pdf

However there is guidance notes for Schedule 2 on page 49 which says

(g) Whilst directors are usually only required to disclose directorships held over the last five
years, the requirements contained in (g)(iv)-(vii) which relate to bankruptcies, receiverships and
liquidations are not limited to the last five years.

Hence, I think there is an innocent enough explanation but the more interesting question is what triggered this check. The aim rules are from July 2016. Hopefully it is part of DD but let's wait and see
oilbagger
Posts: 99
Observation
Opinion:Strong Buy
Price:48.125
RE: Suspicious?
Fri 19:29
For McCarthy appointment the RNS (30/9/2015) is below. It just lists companies where he was a director 5 years ago but mentions Alizyme in the introduction. Perhaps Alizyme wasn't mentioned because it was back in Dec 2009. Could be the AIM rule has changed or was interpreted incorrectly (was within 12 month of his appointment)

Mr McCarthy has a 35 year international business career in high growth biotech, healthcare and technology companies. He is currently Chairman and Non-Executive Director for a number of biotech and healthcare related companies, including Incanthera, Harvard Healthcare and Expedeon Holdings. Mr McCarthy is also the former Chief Executive Officer and Finance Director of a number UK listed public and private companies, including Alizyme plc and Peptide Therapeutics Group plc, and has a core understanding of AIM and its regulatory processes. Co-founding a number of healthcare and biotechnology companies, Mr McCarthy has helped raise substantial amounts of equity capital and also advised and worked at Board level for a diverse range of companies internationally, in areas such as business strategy, mergers & acquisitions, due diligence and licensing.

A Fellow of the Association of Chartered Certified Accountants, Mr McCarthy has an MBA from Cranfield School of Management.

Commenting on Tim McCarthy's appointment, Dimitri Dimitrou, Chief Executive Officer, said:

"We are delighted to have Tim join ImmuPharma as Chairman. This appointment represents a further strong addition to the Board. Tim's commercial and industry background together with capital markets experience will be extremely valuable as ImmuPharma progresses its lead compound, LupuzorTM, through its pivotal Phase III trial, as well as providing guidance on ImmuPharma's long term business strategy."

Current Directorships
Ark Analytics Solutions Limited
BBN International Limited
Dropped Limited
Expedeon Holdings Limited
Frangipani Dreams Limited
Harvard Healthcare Limited
Incanthera Limited
Spear Therapeutics Limited
Unnamed Limited
Wise Old Owl Limited

Directorships in the Last 5 years
Retail Service Team Limited*

*This company entered into a Creditors Voluntary Winding-up on 12th December 2013, 8 months after Mr McCarthy's resignation of directorship. It was dissolved on 4 June 2015.

There are no other disclosures required in relation to Rule 17 or paragraph (g) of Schedule 2 of the AIM Rules for Companies.
oilbagger
Posts: 99
Observation
Opinion:Strong Buy
Price:48.125
RE: Suspicious?
Fri 19:27
The announcement in the RNS is not that important in itself (public knowledge and discussed on advfn before - this should have been included when McCarthy was appointed in 2015 - just carelessness ) but
I have to agree with waterloo1 - there is a possibility that Due Diligence (DD) as part of a deal or takeover has brought this up.
Before everyone gets too exciting it might be just IMM advisors making sure everything is in good shape before negotiations begin.
PinWiz
Posts: 77
Off Topic
Opinion:No Opinion
Price:48.125
RE: Suspicious?
Fri 18:46
Bad news? Really!! Personally I think it looks like T's being crossed and I's being dotted. Regulartories being undertaken, deal en route maybe?
Ridiculous
Posts: 38
Question
Opinion:No Opinion
Price:48.125
Suspicious?
Fri 17:27
Strange that the Aim Rule 17 should be issued after marketclosure on a Fri., giving what looks like bad news.
oilbagger
Posts: 99
Answer
Opinion:Strong Buy
Price:48.125
RE: Post from Watterloo1 - Part 2
Fri 17:02
PinWiz - easy done - good thing is that SP has recovered some ground
PinWiz
Posts: 77
Off Topic
Opinion:No Opinion
Price:48.00
RE: Post from Watterloo1 - Part 2
Fri 15:07
OB lol suppose I could have copied it over;))




Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk






Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.